confirmed by completed Phase 1 clinical trial and by articles published in The Lancet, peer reviewed medical journal. Also the 10-Q has the following paragraph which mentions the "product", so if you are going to refer to the 10-Q you should make sure it says what you claim, for those of you who say there is no product you are in direct contradiction to the 10-Q. Also, there is no where in the 10-Q any mention of waiting 10 years for sales. Paragraph 1 "OphthalmologyTM therapeutics. The most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, the Company has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The Company’s intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy technologies. The Company has no therapeutic products currently available for sale and does not expect to have any therapeutic products commercially available for sale for a period of years, if at all. These factors indicate that the Company’s ability to continue research and development activities is dependent upon the ability of management to obtain additional financing as required."
If the Phase 2 trials are pivotal trials and are as successful as Phase 1, then I would expect that sales could happen quickly, given the test results and the large un-met need.
NASDAQ now shows 30 institutional buyers and ZERO sold positions!! Nice update. This company will; have plenty of money cause they're selling a lot of shares, now that the word is getting out.
“For the first time a pluripotent stem cell derived therapy is about to enter a pivotal trial for Stargardt’s Disease and phase 2 clinical trials for dry Age Related Macular Degeneration
“These new patents bolster an already robust patent estate. This is important as we continue to invest in the clinical development of these innovative new therapies for macular degeneration,” said Dr. Eddy Anglade, Chief Medical Officer of Ocata. “For the first time a pluripotent stem cell derived therapy is about to enter a pivotal trial for Stargardt’s Disease and phase 2 clinical trials for dry Age Related Macular Degeneration, bringing the possibility of these long awaited therapies that much closer to reality.”
Yes, I agree, there will always be dilution as a company grows and develops products, as a successful company they will issue and sell more shares. profitability and share value will be determined by product development and income derived from sales. For right now, considering the monetary potential of diversified stem cell products, they don't have too many shares.
Love the potential here. And the numbers you mention are just for one therapy. I see Phase 2 being a foregone conclusion, that's why institutions are already buying in. They will increase their commitments as the share price increases and as the programs advance. Ocata has a long and deep pipeline forthcoming with potentially hundreds of regenerative therapies they will develop solo or license to partners. Yes the people who bought 11 years ago may have lost, that is the nature of market timing and so it goes with early stage companies and those companies bringing innovative technologies to the market. However, if the early arrivals stuck around they will well get their investments back and much more and folks that are coming to Ocata now don't face the same uncertainty. Just reading the personnel roster of this company is inspirational and when you throw the patent estate on top of that there is no doubt Ocata will excel.
I agree this will be another important conference in getting the word out, there is tremendous potential in this technology and Ocata will come up with the money they need by selling more shares. Companies with a fraction of Ocata's IP have much higher market caps simply because they are better known.
Someone commenting on the acquisition of AOL by Verizon stated that on may 5th Goldman Sachs rated AOL as a "sell" and said there was no reason to own the stock. The SP was $38 at the time. VZ is acquiring AOL for $50 share as of May 12th.
Shareholders can be pro-active by contacting mutual and investment funds and companies like Blackrock (BLK).
Are treating inherited blindness using gene therapy and I think they are using using Benitec's technology to insert DNA construct in cell nuclei. It looks like they have already had a degree of success treating inherited blindness this way, so there doesn't appear to be any question that the HCV therapy will work.
Well guess what, you have these blabbermouths at the corrupt Fed jacking their jaws about how the stock market is overpriced, well maybe you'd like to invest in government bonds, hardy, har, har, guess what money has to go somewhere and a therapy for cancer is a pretty good place to go. Keep in mind, if you're not a day trader you are investing for the future and there are going to be ups and downs in the market. Since the Federal Reserve took over management of the economy in 1913 they have run the US into the round a dollar is now worth $.04 so why would you want to listen to the degenerates who usurped Constitutional Authority over the money supply and have now devalued the currency till it is worth almost nothing. Have you ever asked yourself how the world's (second) largest economy could be so deep in debt and still manage to throw away hundreds of billions of dollars on non-productive escapades all over the world when it can't even provide full employment for its own citizens?
If a bank tells you something you don't want to hear I just close the account and contact the Dept of Banking and Insurance or the state's Attorney General. There are as many banks as drug stores in almost every neighborhood so don't be lazy. Also. many banks have different types of accounts that don't have fees. Good luck, hope you stick it to the phony banks.
Spark injects the back of eye using AAV2 to load corrected genetic instructions into cells that produce proteins necessary for vision. There are a substantial number of inherited genetic deficiencies that can be treated this way and Spark, like Ocata plans to use this gene therapy platform to treat a host of inherited genetic conditions in a variety of areas, not just vision. They are progressed in trials and that gene therapy has been around longer and is more familiar in concept to a larger number of people than stem cell therapy which probably accounts for their larger market cap. Their method of genetically adjusting incorrectly coded cells does not seem therapeutically as beneficial as replacing the deficient cells with brand new correctly differentiated cells, which don't contain the inherited genetic defects.
I have to read up on Spark's therapy. Maybe the benefit of their gene therapy is limited b the lifespan of the cells they are treating. As the treated cells die off and replace themselves the therapy may fade. Anyone know the lifespan of the cells they are treating or have the specifics of their therapy?